

Update on Work Group 4 Post Market

26th GHWP Annual Meeting

15 Feb 2023

Riyadh, The Kingdom of Saudi Arabia

WG 4 Post Market (1)



Chair: Mr. Yorkie CHOW (Medical Device Division, Department of Health, Hong Kong SAR, China)

Co-Chair: Ms. Kitty MAO (GE Healthcare, Singapore)

Advisors: Dr. Jorge GARCIA (Medical Devices Branch TGA, Australia)

Ms Joanna KOH (Mdnet Regulatory Consultants, Singapore)

WG 4 Post Market (2)



Regulator

1. Ms. Aisha AL-GHAITHI

Mr. Ahmed ALQARNI

3. Mr. Alex CHOI

4. Ms. Althea LAU

5. Mr. Karl LEUNG

6. Ms Nancy PRESSLY

Sultanate of Oman

Kingdom of Saudi Arabia

Hong Kong SAR, China

Hong Kong SAR, China

Hong Kong SAR, China

United States of America

Medical Device Industry

1.	Ms. Chueh-pin CHEN	Chinese Taipei
2.	Ms. Judy CHEUNG	United States of America
3.	Ms. Jacqui CUI	People's Republic of China
4.	Ms. Laleetha DFVI	Malavsia

5.	Mr. Prashanth SRIRANGAM	India

6. Ms. Terrenz LEUNG	Hong Kong SAR, China
----------------------	----------------------

7. Ms. Carrie Ll	Hong Kong SAR, China
------------------	----------------------

Updates



Activities

- Formulation and implementation of WG4 work plan
- WG Tele-con meetings: 21 May 2020, 23 Nov 2021 & 19 Jan 2023
- WG4 internal e-mail updates: 1 Mar 2021, 22 Nov 2021, 23 Nov 2021, 24 Oct 2022
- Regular progress updates to TC

Work Plan from 2020



Work Item	Description	Deliverables	Timeline
1	Updating the Post-market Resource Centre (PMRC)	 Updates hyperlinks and information posted in the PMRC Updates: Once / Twice a year 	On-going
2	Gap analysis on the implementation of AHWP guidance among AHWP members	Gap analysis report	Q4,2022
3	Participation in the development works of ISO TC 210/WG6	 Provide comments on drafting the technical document ISO/TR 20416:2020 Medical devices Post-market surveillance for manufacturers 	Q2, 2022
4	Report on post-market support in relation to COVID 19	 Report on post-market support in relation to COVID 19 	Q3, 2022
5	Study on post-market trend in medical devices with AI and cybersecurity	 Report on post-market trend in medical devices with AI and cybersecurity 	Q3, 2023



Purpose

 Develop a "one-stop" location on GHWP website for RAs and MD Industry with convenient access to post-market regulations and reporting information in various jurisdictions

Progress

First launched: 26 Nov 2016

Updates to be done once or twice per year

Last Update: Jan 2023

Coming update: Jul 2023





Link: http://www.ahwp.info/node/809

CAPTCHA

Work Item 2: Gap Analysis on Implementation of AHWP Post-market Guidance (1)



Purpose

- Determine if there is any shortcoming of the GHWP proposed framework and the progress of harmonization among GHWP members
- Identify improvement areas in the work of GHWP on post-market surveillance

- Both hard copy and online version of the survey were prepared, and distributed to AHWP RA members
 via AHWP Secretariat on 24 Sep 2019
- Efforts had been made to encourage response (e.g. reminders to RAs, further extension of submission). The survey was completed on 31 Dec 2022

Work Item 2: Gap Analysis on Implementation of AHWP Post-market Guidance (2)



- Progress
 - As of 31 Dec 2022, only <u>SIX</u> (18.75%) returns were received from 32
 GHWP members:


	Asian Harmoniza	tion Working Party
	AHWP	.1
	Work Group 4 Post-	
	Survey on Adverse Event (AE	
]_	Field Safety Corrective Ac	ctions (FSCA)*
	r Economy.	
Organiz		
	Person	
Contact	E-mail.	
	· —	
Part L	Adverse Event (AE) Reporting (Q1 – Q6)	
Q1.	Does your jurisdiction has an AE Reporting S	System?
	Yes (Go to Q3)	
	☐ No .	
Q2.	What is the reason for not implementing AE	
	There is no medical device regulatory sys The scope of our medical device regulator	•
	We do not have enough resources to imp	
	Other, please specify:	
	- · · · · · -	
Q3.	Does your jurisdiction adopt the AHWP r	recommendation(s) in your AE Reporting
	System?	
4	Yes (Go to Q4(a)- (d))	
	No (Go to Q5).	
4		
Q4.	To what extent, has your AE Reporting System	
(a).	Does your jurisdiction adopt the following A AHWP? (Ref: Section 6 in AHWP/WG4/F001:.	
	Classification	Timeframe.
	Serious public health threat	Within 48 hours
	Unanticipated death or	
	unanticipated serious injury.	Not later than 10 elapsed calendar days.
	All other reportable events	Not later than 30 elapsed calendar days.
	Yes	
	No, please specify the AE Reporting time	eframe in your jurisdiction (if any) a
	1/7.:	

Work Item 2: Gap Analysis on Implementation of AHWP Post-market Guidance (3)




- Survey Results Summary Adverse Event (AE) Reporting
 - Five respondents (83.3%) have AE reporting system in place .

CHART 1 AE REPORTING SYSTEM IN PLACE



 Only two respondents (33.3%) adopt the GHWP recommendations in their AE reporting system.

CHART 2 GHWP RECOMMENDATIONS ADOPTED IN AE REPORTING SYSTEM




Work Item 2: Gap Analysis on Implementation of AHWP Post-market Guidance (4)



- Survey Results Summary Adverse Event (AE) Reporting
 - Two respondents (33.3%) think the existing GHWP recommended AE reporting framework could be improved in terms of the AE definition, classification and reporting form.

CHART 3 IMPROVEMENTS TO THE GHWP RECOMMENDED AE REPORTING FRAMEWORK




Work Item 2: Gap Analysis on Implementation of AHWP Post-market Guidance (5)



- Survey Results Summary Field Safety Corrective Actions (FSCA)
 - Five respondents (83.3%) have FSCA reporting system in place (Chart 4).
 - ALL respondents have not adopted GHWP recommendations in the FSCA reporting system.
 - ALL respondents indicate that they have similar FSCA definition and types of FSCA as GHWP
 - One (16.7%) suggested GHWP could improve the existing recommended FSCA reporting system by providing more guidance on the FSCA reporting timeframe, classification and trending.

CHART 4 FSCA REPORTING SYSTEM IN PLACE



Work Item 2: Gap Analysis on Implementation of AHWP Post-market Guidance (6)



Conclusion and Observations

- In light of the 32 GHWP Member Economies, the number of returns (six only) was comparatively small.
 Hence, the survey results may not be reflecting the whole picture for GHWP members at large.
- Even though the data may not be very significant, they did shed some light on the areas where the Working Group should focus on the way forward, such as reviewing and aligning the GHWP Recommendation on PMS.

Work Item 3: Participation in the Development Work of the ISO TC 210/WG6



Purpose

Liaise with ISO TC210/WG6 regarding the development of the technical reference document: ISO
 TR20416 Medical devices – Post-market surveillance for manufacturers

- The document ISO/TR 20416:2020 Medical devices Post-market surveillance for manufacturers was published in Jul 2020. No further actions for WG4.
- WG4 will continue to liaise with ISO TC210/WG6 on post-market areas to promote global regulatory harmonisation and convergence.

Work Item 4: Report on post-market support in relation to COVID-19



Purpose and Rationale

 Explore the post-market support in relation to COVID-19 in different jurisdictions during the COVID-19 pandemic

- Work progress was affected by the COVID-19 pandemic.
- Study write-up is being compiled.

Work Item 5: Study on post-market trend in medical devices with AI and cybersecurity



Purpose and Rationale

Explore the post-market trend in medical devices with AI and cybersecurity in different jurisdictions

- The matter is in many jurisdictions outside the purview of the medical device regulatory authority,
 making the collection and understanding of relevant statutory information very difficult.
- WG4 is still trying to collect more information and complete a report by the work item end date of Q3,
 2023



End of Update on WG4

